U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H24F2N2O3.2ClH
Molecular Weight 463.346
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFLETIRIZINE DIHYDROCHLORIDE

SMILES

Cl.Cl.OC(=O)COCCN1CCN(CC1)C(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3

InChI

InChIKey=HQWVDUUIOCFXPO-UHFFFAOYSA-N
InChI=1S/C21H24F2N2O3.2ClH/c22-18-5-1-16(2-6-18)21(17-3-7-19(23)8-4-17)25-11-9-24(10-12-25)13-14-28-15-20(26)27;;/h1-8,21H,9-15H2,(H,26,27);2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H24F2N2O3
Molecular Weight 390.4237
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.pharmacodia.com/yaodu/html/v1/chemicals/9c3368c58b7c3569a3e83048cfc8d023.html

Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Quantitation of efletirizine in human plasma and urine using automated solid-phase extraction and column-switching high-performance liquid chromatography.
1999 Jul 9
Antihistamines in late-phase clinical development for allergic disease.
2002 Feb
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
2004 Nov 15
Patents

Sample Use Guides

15, 30 and 60 ug/100 ul (0.15%, 0.3% or 0.6%) twice-daily for two weeks
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:53:22 GMT 2023
Edited
by admin
on Fri Dec 15 15:53:22 GMT 2023
Record UNII
JQ7ZT5MRA0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EFLETIRIZINE DIHYDROCHLORIDE
USAN  
USAN  
Official Name English
UCB 28754
Code English
(2-(4-BIS(P-FLUOROPHENYL)METHYL)-1-PIPERAZINYL)ETHOXY)ACETIC ACID, DIHYDROCHLORIDE
Common Name English
ACETIC ACID, (2-(4-(BIS(4-FLUOROPHENYL)METHYL)-1-PIPERAZINYL)ETHOXY)-, DIHYDROCHLORIDE
Common Name English
UCB-28754
Code English
CP-448 187-01
Code English
EFLETIRIZINE DIHYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
Code System Code Type Description
PUBCHEM
156659
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
NCI_THESAURUS
C72751
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
SMS_ID
300000044478
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
USAN
NN-75
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104290
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID70177056
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
CAS
225367-66-8
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
FDA UNII
JQ7ZT5MRA0
Created by admin on Fri Dec 15 15:53:22 GMT 2023 , Edited by admin on Fri Dec 15 15:53:22 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY